FRONTIER-2:口服JNJ-77242113治疗中重度斑块状银屑病的2b期长期扩展剂量范围研究
FRONTIER-2为FRONTIER-1的长期扩展研究,评估口服IL-23受体信号抑制肽JNJ-77242113治疗中重度斑块状银屑病至1年的疗效与安全性。多数患者(89%)继续进入FRONTIER-2,第16-52周应答率维持稳定,最高应答率多出现在100mg每日两次组。第52周该组PASI75应答率为76%,PASI90为64%,研究者总体评估(IGA)0/1为74%,PASI100为40%,IGA0为43%。第16-56周59%患者出现至少1例不良事件,严重不良事件发生率为4%,未发现安全性信号。
要点
- JNJ-77242113治疗中重度斑块状银屑病至1年皮肤清除应答持久。
- 最高应答率多出现在100mg每日两次组:第52周PASI75为76%。
- 长达56周安全性随访未发现新的安全性信号。
核心结论
- JNJ-77242113治疗中重度斑块状银屑病的皮肤清除应答可持续至1年,且未发现安全性信号。
研究设计与样本
- FRONTIER-2是FRONTIER-1的2b期长期扩展、剂量范围研究。
- FRONTIER-1中患者接受JNJ-77242113每日25mg至每日两次100mg或安慰剂治疗至第16周。
- 完成FRONTIER-1的患者可入组FRONTIER-2,继续相同剂量JNJ-77242113至第52周;安慰剂组患者在第16-52周交叉至JNJ-77242113每日100mg。
- 安全性随访持续至第56周。
主要发现
- 89%的FRONTIER-1患者继续进入FRONTIER-2。
- 从第16周至第52周,各项结局的应答率均维持稳定。
- 最高应答率一般出现在JNJ-77242113每日两次100mg组。
- 第52周时,每日两次100mg组76%的患者达到PASI75。
- 第52周时,每日两次100mg组达到PASI90、IGA 0/1、PASI100和IGA 0的患者比例分别为64%、74%、40%和43%。
关键数值与推荐
- 第52周时,每日两次100mg组PASI75应答率为76%。
- 第52周时,每日两次100mg组PASI90应答率为64%,IGA 0/1应答率为74%。
- 第52周时,每日两次100mg组PASI100应答率为40%,IGA 0应答率为43%。
- 第16-56周,59%接受JNJ-77242113治疗的患者出现至少1例不良事件。
- 研究者认为与治疗无关的严重不良事件发生率为4%。
临床怎么用
- 对于中重度斑块状银屑病,口服JNJ-77242113每日两次100mg可能提供持久的皮肤清除获益。
- 治疗期间需关注不良事件,但长期扩展研究未发现新的安全性信号。
- 该研究为剂量范围探索,临床决策需结合后续更大规模研究数据。
局限性
- 每个治疗组患者数量较少。
- 长期数据为描述性性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study. OBJECTIVE: FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year. METHODS: FRONTIER-1 participants received JNJ-77242113 at doses from 25 mg daily to 100 mg twice daily or PBO through W16. Patients completing FRONTIER-1 could enroll in FRONTIER-2 and continue JNJ-77242113 at the same dose through W52. Those on PBO crossed over to JNJ-77242113 100 mg daily for W16-52. Safety follow-up continued through W56. RESULTS: Most (89%) FRONTIER-1 patients continued to FRONTIER-2. Across outcomes, response rates were maintained from W16-52. The highest response rates generally occurred with JNJ-77242113 100 mg twice daily. At W52, 76% of patients achieved up to 75% improvement in Psoriasis Area and Severity Index (PASI75) with 100 mg twice daily; rates of clear or almost clear skin were 64% (PASI90), 74% (Investigator's Global Assessment 0/1), 40% (PASI100), and 43% (Investigator's Global Assessment 0). From W16-56, 59% of JNJ-77242113-treated patients had ≥1 adverse events. Serious adverse events, considered unrelated to treatment by investigators, occurred in 4% of patients. LIMITATIONS: The study was limited by the small number of patients in each treatment group and the descriptive nature of the longer-term data. CONCLUSION: Rates of skin clearance with JNJ-77242113 were durable to 1 year and no safety signals were identified.
引用
- Ferris LK, Bagel J, Huang YH, et al. FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024. PMID: 39549848. doi:10.1016/j.jaad.2024.10.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。